Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview

S Mondal, N Adhikari, S Banerjee, SA Amin… - European journal of …, 2020 - Elsevier
Matrix metalloproteinases (MMPs) are zinc dependent proteolytic metalloenzyme. MMP-9 is
one of the most complex forms of matrix metalloproteinases. MMP-9 has the ability to …

Inhibitors of gelatinases (MMP-2 and MMP-9) for the management of hematological malignancies

S Das, SA Amin, T Jha - European journal of medicinal chemistry, 2021 - Elsevier
Abstract Matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) are
collectively known as gelatinases whereas MMP-2 is gelatinase-A and MMP-9 is termed as …

Pathological role of HDAC8: cancer and beyond

JY Kim, H Cho, J Yoo, GW Kim, YH Jeon, SW Lee… - Cells, 2022 - mdpi.com
Histone deacetylase 8 (HDAC8) is a class I HDAC that catalyzes the deacetylation of histone
and non-histone proteins. As one of the best-characterized isoforms, numerous studies have …

Chemical-informatics approach to COVID-19 drug discovery: Monte Carlo based QSAR, virtual screening and molecular docking study of some in-house molecules …

SA Amin, K Ghosh, S Gayen, T Jha - Journal of Biomolecular …, 2021 - Taylor & Francis
Abstract World Health Organization characterized novel coronavirus disease (COVID-19),
caused by severe acute respiratory syndrome (SARS) coronavirus-2 (SARS-CoV-2) as …

Matrix metalloproteinases inhibitors in cancer treatment: an updated review (2013–2023)

S Almutairi, HM Kalloush, NA Manoon, SK Bardaweel - Molecules, 2023 - mdpi.com
Matrix metalloproteinases (MMPs) are identifiable members of proteolytic enzymes that can
degrade a wide range of proteins in the extracellular matrix (ECM). MMPs can be …

Are inhibitors of histone deacetylase 8 (HDAC8) effective in hematological cancers especially acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) …

SA Amin, S Khatun, S Gayen, S Das, T Jha - European Journal of Medicinal …, 2023 - Elsevier
Abstract Histone deacetylase 8 (HDAC8) aberrantly deacetylates histone and non-histone
proteins. These include structural maintenance of chromosome 3 (SMC3) cohesin protein …

Profiling the structural determinants of pyrrolidine derivative as gelatinases (MMP-2 and MMP-9) inhibitors using in silico approaches

K Tabti, I Ahmad, I Zafar, A Sbai, H Maghat… - … Biology and Chemistry, 2023 - Elsevier
Quantitative structure activity relationship (QSAR) studies on pyrrolidine derivatives have
been established using CoMFA, CoMSIA, and Hologram QSAR analysis to estimate the …

Chimeric HDAC inhibitors: Comprehensive review on the HDAC‐based strategies developed to combat cancer

HM Hesham, DS Lasheen… - Medicinal Research …, 2018 - Wiley Online Library
Recently, molecular hybridization paradigm became an interesting and smart way to defeat
the multifaceted cancer disease by a single molecular entity that acts via several …

Selective inhibitors of medium-size S1′ pocket matrix metalloproteinases: a stepping stone of future drug discovery

SK Baidya, S Banerjee, N Adhikari… - Journal of Medicinal …, 2022 - ACS Publications
Among various matrix metalloproteinases (MMPs), MMPs having medium-size S1′ pockets
are established as promising biomolecular targets for executing crucial roles in cancer …

Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective

Y Gao, H Zhang, F Lirussi, C Garrido, XY Ye… - Biochemical …, 2020 - Elsevier
Epigenetic enzymes histone deacetylases (HDACs) are clinically validated anticancer drug
targets which have been studied intensively in the past few decades. Although several drugs …